Last checked at 23 Jul 2020 13:00
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Result of AGM
ValiRx Plc (AIM: VAL) announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
The proxy votes are set out below:-
Resolutions | For | Against | Discretion |
Resolution 1 - Receive the annual report and accounts | 4,612,178 | 0 | 2,000 |
Resolution 2 - Re-appoint Gerry Desler as a director | 4,226,311 | 377,739 | 2,000 |
Resolution 3 - Re-appoint Dr Suzanne Dilly as a director | 4,579,542 | 23,437 | 2,000 |
Resolution 4 - Re-appoint Martin Lampshire as a director | 4,579,542 | 24,623 | 2,000 |
Resolution 5 - Re-appoint Dr Kevin Cox as a director | 4,580,958 | 23,207 | 2,000 |
Resolution 6 - Re-appoint the auditors | 4,573,342 | 26,058 | 2,000 |
Resolution 7 - Set the auditors' remuneration | 4,548,033 | 49,943 | 2,000 |
Resolution 8 - Provide authority to allot share capital | 4,441,339 | 62,857 | 2,008 |
Resolution 9 - Provide authority to dis-apply statutory pre-emption rights (Special Resolution) | 4,436,339 | 67,857 | 2,008 |
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
*** ENDS ***
For more information, please contact:
ValiRx plc | Tel: +44 (0) 20 7073 2628 www.valirx.com |
Suzanne Dilly | Suzanne.Dilly@valirx.com |
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti | Tel: +44 (0) 20 7213 0880 |
Peterhouse Capital Limited (Sole Broker) Duncan Vasey / Lucy Williams / Eran Zucker | Tel: +44 (0) 20 7469 0930 |
Notes for Editors
About ValiRx
ValiRx PLC accelerates the development of innovative medicines that enhance patient experience. We do this by combining intellectual and financial resources to select, progress and partner a balanced portfolio of risk-reduced, early-stage technologies for translation into clinical candidates.
The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.